- Not yet recruiting
NCT05461209: Phase 3: Talquetamab Vs Belantamab Mafodotin RRMM - (MonumenTAL-5)
(MonumenTAL-5)
NCT05461209: Phase 3: A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5)
NCT05461209: Phase 3: A Study of Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma (MonumenTAL-5)
The purpose of this study is to compare the efficacy of talquetamab versus belantamab mafodotin in terms of overall response rate (ORR) or progression-free survival (PFS).
Sponsor
Janssen Research & Development, LLC
ClinicalTrials.gov Identifier: NCT05461209
Official Title: A Phase 3 Study Comparing Talquetamab to Belantamab Mafodotin in Participants With Relapsed/Refractory Multiple Myeloma Who Have Received at Least 4 Prior Therapies Including an Immunomodulatory Drug, a Proteasome Inhibitor, and an Anti-CD38 Antibody
First Posted : July 18, 2022
Click here to see details on ClinicalTrials.gov
Talquetamab (Code C171840)
Anti-CD3/Anti-GPRC5D Bispecific Monoclonal Antibody JNJ-64407564
GPRC5D x CD3 Bispecific Antibody JNJ-64407564
GPRC5D x CD3 DuoBody Antibody JNJ-64407564
GPRC5D/CD3 DuoBody Antibody JNJ-64407564
Humanized GPRC5D x CD3 DuoBody Antibody JNJ-64407564
JNJ 64407564
JNJ-64407564
JNJ64407564
Talquetamab
TALQUETAMAB
Drug: Talquetamab
Drug: Belantamab Mafodotin
Locations
United States, Arkansas
United States, California
United States, District of Columbia
United States, Louisiana
United States, Maryland
United States, Massachusetts
United States, Michigan
United States, Minnesota
United States, Missouri
United States, New Jersey
United States, North Carolina
United States, Ohio
United States, Pennsylvania
United States, Texas
United States, Utah
United States, Wisconsin
Canada, Nova Scotia
Canada, Ontario
Canada, Quebec
Canada
Europe
Czechia
Germany
Israel
Italy
Poland
Portugal
Spain
United Kingdom
RELATED POSTS
TECLISTAMAB STUDIES:
NCT03145181: Phase 1 - Teclistamab, Humanized BCMA*CD3 Bispecific Ab, in Relapsed Myeloma (MajesTEC1)
NCT04557098: Phase 2- Teclistamab, in Participants With Relapsed or Refractory Myeloma (MajesTEC-1)
NCT05083169: Phase 3 - Tec-Dara Vs DPd Vs DVd in Relapsed or Refractory Myeloma - (MajesTEC-3)
NCT05243797: Phase 3: Tec + Len Vs Len Alone in NDMM as Maintenance Therapy Post ASCT (MajesTEC-4)
NCT04722146: Phase 1b - Teclistamab With Other Anticancer Therapies in Participants With Myeloma
NCT05231629: Phase 2: Sequential Therapy in Multiple Myeloma Guided by MRD Assessments (MASTER-2)
TALQUETAMAB STUDIES:
NCT04634552: Phase 2 - A Study of Talquetamab in Participants With Refractory Multiple Myeloma
NCT05050097: Phase 1 - A Study of Talquetamab With Other Anticancer Therapies in Multiple Myeloma
NCT04773522: Phase 1 - JNJ-64407564 in Japanese Participants With Relapsed or Refractory Myeloma
TECLISTAMAB AND TALQUETAMAB STUDIES:
NCT04586426: Phase 1b - Talquetamab and Teclistamab in Relapsed or Refractory Multiple Myeloma
NCT04108195: Phase 1b - Subcutaneous Dara With Bispecific T Cell Redirection Antibodies - TRIMM-2